Using RNA therapies to treat Alzheimer's disease
Official title: Treating Alzheimer's Disease with PMO RNA Therapeutics
Funded at University of California, San Diego · NIH-11037379 · Data updated 2026-11-12
This study is exploring a new type of treatment using RNA technology to help people with Alzheimer's by targeting the root cause of the disease, aiming to reduce harmful proteins in the brain that lead to memory problems.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Diego NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project start | December 1, 2024 |
| Project end | November 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $238,500 |
| NIH project number | 1R21NS140937-01 |
| Project ID | NIH-11037379 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with Alzheimer's disease who are experiencing cognitive decline.
✕Less likely to help
Patients with other forms of dementia or those who do not have a diagnosis of Alzheimer's disease may not benefit from this research.
What this research studies
This research investigates the potential of RNA therapeutics to target the underlying causes of Alzheimer's disease, specifically focusing on the Amyloid Precursor Protein (APP) and its role in the disease's progression. By utilizing advanced RNA technology, the study aims to develop treatments that can selectively inhibit the production of harmful amyloid-beta peptides, which are responsible for the formation of plaques in the brain. The approach is designed to provide a more effective solution compared to existing therapies that only address symptoms rather than the root cause. Patients may be monitored for changes in cognitive function and overall brain health as part of the treatment process.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that slows or halts the progression of Alzheimer's disease, improving quality of life for patients.
How similar studies have gone: Previous research has shown promise in using RNA therapeutics for various conditions, indicating potential success for this novel approach in treating Alzheimer's disease.
Where this research is happening
-
University of California, San Diego
La Jolla, United States Active
Researchers
- Principal investigator: Dowdy, Steven F — University of California, San Diego
- Study coordinator: Dowdy, Steven F
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.